Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Madrigal Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$197.72M. For fiscal 2025 it was -$189.55M. The highest annual figure on record is -$3.14M in fiscal 2015.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$189.55M | – |
| FY2024 | Dec 31, 2024 | -$455.57M | – |
| FY2023 | Dec 31, 2023 | -$324.23M | – |
| FY2022 | Dec 31, 2022 | -$224.86M | – |
| FY2021 | Dec 31, 2021 | -$183.92M | – |
| FY2020 | Dec 31, 2020 | -$157.56M | – |
| FY2019 | Dec 31, 2019 | -$41.62M | – |
| FY2018 | Dec 31, 2018 | -$25.51M | – |
| FY2017 | Dec 31, 2017 | -$22.32M | – |
| FY2016 | Dec 31, 2016 | -$17.61M | – |
| FY2015 | Dec 31, 2015 | -$3.14M | – |
| FY2014 | Dec 31, 2014 | -$78.93M | – |
| FY2013 | Dec 31, 2013 | -$77.41M | – |
| FY2012 | Dec 31, 2012 | -$54.14M | – |
| FY2011 | Dec 31, 2011 | -$47.30M | – |
| FY2010 | Dec 31, 2010 | -$38.20M | – |
| FY2009 | Dec 31, 2009 | -$26.81M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $23.33M | – |
| Q1 FY2026 | Mar 31, 2026 | -$167.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$133.46M | – |
| Q3 FY2025 | Sep 30, 2025 | $79.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$47.05M | – |
| Q1 FY2025 | Mar 31, 2025 | -$88.89M | – |
| Q4 FY2024 | Dec 31, 2024 | -$104.49M | – |
| Q3 FY2024 | Sep 30, 2024 | -$66.98M | – |
| Q2 FY2024 | Jun 30, 2024 | -$134.95M | – |
| Q1 FY2024 | Mar 31, 2024 | -$149.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$79.93M | – |
| Q3 FY2023 | Sep 30, 2023 | -$84.92M | – |
| Q2 FY2023 | Jun 30, 2023 | -$75.31M | – |
| Q1 FY2023 | Mar 31, 2023 | -$84.07M | – |
| Q4 FY2022 | Dec 31, 2022 | -$58.52M | – |
| Q3 FY2022 | Sep 30, 2022 | -$59.07M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.36M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$48.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$45.56M | – |
| Q2 FY2021 | Jun 30, 2021 | -$46.88M | – |
| Q1 FY2021 | Mar 31, 2021 | -$43.43M | – |
| Q4 FY2020 | Dec 31, 2020 | -$54.95M | – |
| Q3 FY2020 | Sep 30, 2020 | -$47.85M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.26M | – |
| Q1 FY2020 | Mar 31, 2020 | -$30.51M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.28M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$11.54M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.48M | – |
| Q4 FY2018 | Dec 31, 2018 | -$6.27M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.24M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.36M | – |
| Q1 FY2018 | Mar 31, 2018 | -$8.64M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.95M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.95M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.65M | – |
| Q1 FY2017 | Mar 31, 2017 | -$3.77M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.28M | – |
| Q3 FY2016 | Sep 30, 2016 | -$9.24M | – |
See a number that looks wrong?